The U.S. Government and Global Polio Efforts
This fact sheet provides a snapshot of global polio eradication efforts and examines the U.S. government’s role in addressing polio worldwide.
View the Latest: Federal Budget
Filter
-
-
U.S. Global Funding for COVID-19 by Country and Region: An Analysis of USAID Data
Issue BriefAs Congress again considers increased assistance for the global response to COVID-19, we look at how current U.S. global COVID-19 emergency funding is being channeled, particularly to countries and regions.
-
The Growth in Share of Medicare Advantage Spending
FeatureEarlier this week, the Biden Administration announced the final Medicare Advantage rates for 2023, which are projected to result in an average increase in Medicare Advantage plan revenue of 8.5% compared to 2022 - the highest average expected increase in recent years.
-
Implications of the Lapse in Federal COVID-19 Funding on Access to COVID-19 Testing, Treatment, and Vaccines
Issue BriefA current impasse in Congress threatens continued funding for COVID-19 testing, treatment, and vaccines. The lack of additional federal COVID-19 funding has broad implications for access to these services, particularly for the uninsured, and could undermine efforts to ensure equitable access to these resources.
-
Dec. 8 Event: Unpacking the Prescription Drug Provisions of the Build Back Better Act
Event Date:EventAs the Build Back Better Act shifts from the House to the Senate, there’s considerable interest in provisions that would lower the cost of prescription drugs.
-
The U.S. Congress and Global Health: A Primer
ReportThis primer provides an overview of congressional engagement in global health. It examines the structure of Congress and its role and key activities in global health. It then illustrates these by examining two global health examples: the creation and evolution of PEPFAR and the 2014/2015 Ebola outbreak in West Africa.
-
Payments to Medicare Advantage Plans Boosted Medicare Spending by $7 Billion in 2019
News ReleaseThe federal government spent $321 more per person for beneficiaries enrolled in Medicare Advantage plans than for those in traditional Medicare in 2019, a gap that amounted to $7 billion in additional spending on the increasingly popular private plans that year, finds a new KFF analysis.
-
Higher and Faster Growing Spending Per Medicare Advantage Enrollee Adds to Medicare’s Solvency and Affordability Challenges
Issue BriefThis analysis finds that Medicare spending for Medicare Advantage enrollees was $321 higher per person in 2019 than if enrollees had instead been coverage by traditional Medicare, leading to an estimated $7 billion in additional spending in 2019. It also examines the implications of expected growth in Medicare Advantage enrollment and payments per enrollee from 2021 to 2029.
-
What’s the Latest on Medicare Drug Price Negotiations?
Issue BriefIn response to prescription drug spending growth and heightened attention to drug prices, some policymakers have proposed allowing the federal government to negotiate the price of prescription drugs for Medicare and private payers. This brief describes the current status of drug price negotiation proposals, looks back at the history of proposals to give the federal government the authority to negotiate drug prices in Medicare, describes the negotiation provisions in key legislation (H.R. 3), and discusses the potential spending effects for the federal government, beneficiaries, and private payers.
-
Historical Trends in U.S. Funding for Global Health
Issue BriefTo provide context for the release of the administration’s first, full budget request for FY 2022, this brief provides an overview of historical trends in U.S. global health funding, including changes in program-specific funding over time, the distribution between bilateral and multilateral support, and in the increasing use of emergency supplemental funding in response to outbreaks.